Adult Routine reversal Recommended dose: 4 mg/kg as single IV bolus inj if recovery has reached at least 1-2 post-tetanic counts or 2 mg/kg as single IV bolus inj if spontaneous recovery has occurred up to reappearance of T2 following rocuronium- or vecuronium-induced blockade. Immediate reversal of rocuronium-induced blockade 16 mg/kg as single IV bolus inj 3 min after bolus dose of rocuronium Br 1.2 mg/kg. Recurrence of neuromuscular blockade post-op Repeat dose of 4 mg/kg after initial dose of 2 mg/kg or 4 mg/kg. Childn & adolescent 2-17 yr Routine reversal of rocuronium-induced blockade 2 mg/kg as single IV bolus inj at reappearance of T2.
Hypersensitivity. Not to be used to reverse block induced by nonsteroidal neuromuscular blocking agents eg, succhinycholine or benzylisoquinolinium compd; for reversal of neuromuscular blockade induced by steroidal neuromuscular blockers other than rocuronium or vecuronium; reversal of pancuronium-induced blockade. Recurrence of neuromuscular blockade; signs of light anesth; marked bradycardia. Delayed recovery time in CV disease, oedematous stage. Monitor resp function during recovery; coagulation parameters in patients w/ known coagulopathies & those using anticoagulants; hemodynamic changes during & after reversal. Patients receiving rocuronium or vecuronium in ICU setting; on controlled Na diet. Concomitant use w/ medicinal products which potentiate neuromuscular blockade in post-op; hormonal contraceptives; toremifene, fusidic acid. Not recommended in severe renal impairment including those requiring dialysis. Severe hepatic impairment; hepatic impairment accompanied by coagulopathy. Pregnancy & lactation. Not recommended in term newborn infants & infants. Not recommended in immediate reversal in childn & adolescents. Delayed recovery time in elderly.
Sign Out
 100 mg_mL3f889b97-e486-4a04-868a-9faa000a2fcb.GIF)
